56 results about "Conjugated fatty acid" patented technology

Methods for enhancing the release and / or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and / or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

The present invention relates to fatty acids. In particular, the present invention provides polyconjugated fatty acids, and methods of their synthesis and their use.

Treatment of carcinoma in a human is disclosed, including administering a therapeutically effective amount of a fatty acid having four carbons with two conjugated double bonds formed by reacting an ester of a fatty acid with a tosyl chloride or a mesyl chloride, the fatty acid having four carbon atoms such that carbon one bears one hydrogen and one hydroxyl group, carbon two bears two hydrogens, and a double bond is positioned between carbon three and four. The tosylate or mesylate of the ester of the fatty acid having the chain of four carbon atoms such that carbon one bears one hydrogen and one hydroxyl group, carbon two bears two hydrogens, and a double bond is positioned between carbon three and four is reacted with diazabicyclo-undecene. The method includes administering to a human a highly purified fatty acid in accordance with the present invention.

Methods for treating or preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation are disclosed. The compositions contain a conjugated fatty acid, a thiol-containing compound and a bioavailable form of trivalent chromium.

Processes for preparing conjugated fatty acid glycerides comprising: (a) isomerizing a fatty acid lower alkyl ester corresponding to the general formula (I) in the presence of a basic catalyst at a temperature of from 100 to 160° C., to form a conjugated fatty acid lower alkyl ester:R1CO—OR2  (I)wherein R1CO represents an acyl radical having from 16 to 22 carbon atoms and at least two carbon-carbon unsaturations and R2 represents an alkyl radical having from 1 to 4 carbon atoms; and (b) transesterifying the conjugated fatty acid lower alkyl ester with glycerol to form a conjugated fatty acid glyceride, wherein a lower alkanol corresponding to the general formula R2OH is formed, wherein R2 is as defined above, and the lower alkanol is continuously removed from the transesterification reaction; are described.

A conjugated fatty acid glyceride, which is formed by converting conjugated fatty acids having conjugated double bond(s) in the molecule into glycerol esters, to more effectively exert the inherent physiological effects of the conjugated fatty acids and control the bitterness or astringency of the conjugated fatty acids, thereby making the conjugated fatty acids suitable for oral intake. These conjugated glycerides (for example, glycerides having conjugated linoleic acid in the molecule) have effects of improving lipid metabolism, treating obesity and treating hypertension.